1
Empagliflozin in Diuretic Refractory Ascites
Condition(s):Liver Cirrhosis; Cirrhosis; Ascites; Ascites Hepatic; Sodium-Glucose Transporter 2 InhibitorsLast Updated:October 21, 2022Recruiting
Empagliflozin 10 MG: 163 Clinical Trials, Page 1 of 17
Hide Studies Not Open or Pending
2
Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Japanese Patients With Type 2 Diabetes Mellitus
Condition(s):Diabetes Mellitus, Type 2Last Updated:September 6, 2018Completed
3
Metabolic Effects of the SGLT-2 Inhibitor Empagliflozin in Patients With Diabetic Nephropathy (MEDiaN)
Condition(s):Diabetic NephropathiesLast Updated:December 17, 2020Terminated
4
Effects of Empagliflozin on Fibrosis and Cirrhosis in Chronic Hepatitis B
Condition(s):Chronic Hepatitis b; NAFLD; Cirrhosis; Fibrosis, Liver; Empagliflozin; SGLT2 InhibitorsLast Updated:June 3, 2022Recruiting
5
Effect of Empagliflozin on Liver Fat in Non-diabetic Patients
Condition(s):Non-alcoholic Fatty Liver DiseaseLast Updated:May 25, 2022Active, not recruiting
6
The Effect of Morning Versus Evening Administration on The Pharmacokinetics and Pharmacodynamics of Empagliflozin
Condition(s):Diabetes Mellitus; Pharmacokinetics; PharmacodynamicsLast Updated:April 2, 2019Completed
7
Empagliflozin for New On-set Heart Failure Study Regardless of Ejection Fraction
Condition(s):Acute Heart FailureLast Updated:October 4, 2022Recruiting
8
Effect of Empagliflozin on Urinary Excretion of Adenosine and Osteocyte Function in Patients With Chronic Kidney Disease
Condition(s):Chronic Kidney Disease stage3Last Updated:July 14, 2021Recruiting
9
Studies of Empagliflozin and Its Cardiovascular, Renal and Metabolic Effects
Condition(s):Heart Failure; Diabetes MellitusLast Updated:September 18, 2020Completed
10
Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Background Metformin in Patient With Type 2 Diabetes
Condition(s):Diabetes Mellitus, Type 2Last Updated:April 4, 2016Completed